Search results for Tigatuzumab ELISA Kit
Tigatuzumab ELISA Kit, ProteoGenix, KPTX115
Description of Tigatuzumab ELISA Kit Tigatuzumab ELISA Kit: A Comprehensive Overview Introduction Tigatuzumab is a monoclonal antibody that has been developed as a potential therapeutic agent for various types of cancer. It specifically targets a protein called death receptor 5 (DR5), which is overexpressed in many cancer cells. The Tigatuzumab ELISA kit is a valuable tool for researchers and clinicians to measure the levels of Tigatuzumab in biological samples. Structure of Tigatuzumab Tigatuzumab is a humanized IgG1 monoclonal antibody, meaning that it is derived from human antibodies but has been modified for therapeutic use. It has a molecular weight of approximately 150 kDa and consists of two heavy chains and two light chains. The antibody binds to DR5 with high affinity and specificity, making it a promising therapeutic agent. Activity of Tigatuzumab The main mode of action of Tigatuzumab is through its binding to DR5. This leads to the activation of the death receptor signaling pathway, ultimately resulting in the induction of apoptosis (programmed cell death) in cancer cells. Tigatuzumab has also been shown to have anti-angiogenic effects, meaning that it can inhibit the formation of new blood vessels that are necessary for tumor growth and metastasis. Application of Tigatuzumab ELISA Kit The Tigatuzumab ELISA kit is a valuable tool for measuring the levels of Tigatuzumab in various biological samples, such as serum, plasma, and cell culture supernatants. This allows researchers to monitor the pharmacokinetics (movement within the body) of Tigatuzumab and to determine the optimal dosage for therapeutic use. The kit is also useful for measuring the levels of Tigatuzumab in clinical trials, providing valuable information on the efficacy and safety of the antibody. Benefits of Using Tigatuzumab ELISA Kit The use of the Tigatuzumab ELISA kit offers several advantages over other methods of measuring Tigatuzumab levels. It is a highly sensitive and specific assay, allowing for accurate and precise measurements. The kit is also user-friendly and can be easily performed in a laboratory setting. Additionally, the Tigatuzumab ELISA kit is cost-effective and can be used to analyze a large number of samples simultaneously, making it a valuable tool for high-throughput screening. Conclusion In summary, the Tigatuzumab ELISA kit is a valuable tool for researchers and clinicians studying the potential therapeutic effects of Tigatuzumab. It provides a comprehensive and accurate measurement of Tigatuzumab levels, allowing for the optimization of treatment strategies for cancer patients. The high specificity and sensitivity of the kit make it a reliable tool for monitoring the pharmacokinetics of Tigatuzumab and assessing its efficacy in clinical trials. With the increasing interest in targeting DR5 as a therapeutic approach for cancer, the Tigatuzumab ELISA kit will continue to play a crucial role in advancing research and treatment in this field.
Host
Reactivity
Applications
Conjugation
Tigatuzumab ELISA Kit, Abbexa, abx395004
Tigatuzumab ELISA Kit is a quantitative ELISA kit for detection of Tigatuzumab.Tigatuzumab is the humanized version of the agonistic murine monoclonal antibody TRA-8 that binds to the death receptor 5 and induces apoptosis of human cancer cell lines via the caspase cascade. The combination of tigatuzumab and gemcitabine inhibits tumor growth in murine pancreatic xenografts. This phase 2 trial evaluated the efficacy of tigatuzumab combined with gemcitabine in 62 chemotherapy-naive patients with histologically or cytologically confirmed unresectable or metastatic pancreatic cancer. Patients received intravenous tigatuzumab (8 mg/kg loading dose followed by 3 mg/kg weekly) and gemcitabine (1000 mg/m(2) once weekly for 3 weeks followed by 1 week of rest) until progressive disease (PD) or unacceptable toxicity occurred. The primary end point was progression-free survival (PFS) at 16 weeks. Secondary end points included objective response rate (ORR) (complete responses plus partial responses), duration of response, and overall survival (OS). Safety of the combination was also evaluated. Mean duration of treatment was 18.48 weeks for tigatuzumab and 17.73 weeks for gemcitabine. The PFS rate at 16 weeks was 52.5% (95% confidence interval [CI], 39.3-64.1%). The ORR was 13.1%; 28 (45.9%) patients had stable disease and 14 (23%) patients had PD. Median PFS was 3.9 months (95% CI, 2.2-5.4 months). Median OS was 8.2 months (95% CI, 5.1-9.6 months). The most common adverse events related to tigatuzumab were nausea (35.5%), fatigue (32.3%), and peripheral edema (19.4%). Tigatuzumab combined with gemcitabine was well tolerated and may be clinically active for the treatment of chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.